Financial capital versus medical-industrial complex: Challenges for the regulatory agencies;Capital financiero versus complejo médico-industrial: Los desafíos de las agencias regulatorias

Ciencia e Saude Coletiva

Volumn 13, Issue 5, 2008, Pages 1619-1626

  Iriart, Celia ^a  

^a NONE

Author keywords

Distribution dispute; Financial capital; Health sector reform; Latin America; Medical industrial complex; Regulation

Indexed keywords

EID: 53349142389     PISSN: 14138123     EISSN: 16784561     Source Type: Journal    
DOI: 10.1590/s1413-81232008000500025     Document Type: Note

References (37)

1. Iriart C, Waitzkin H, Merhy E, Estrada A, Breilh J. Atención gerenciada en América Latina: su papel en la reforma de los sistemas de salud: Buenos Aires, Argentina: Instituto de Estudios y Formación/Central de Trabajadores Argentinos; 1999.
2. Waitzkin H, Iriart C. Global trade and U.S. health policies [proyecto de investigación]. Bethesda, Maryland: NIH/Agency for Health Care Research and Quality; 2003-2005.
3. Waitzkin H, Iriart C. Mental health services and global trade [proyecto]. Bethesda, Maryland: National Institute of Mental Health; 2003-2005.
4. Iriart C. The transnationalization of the health care system in Argentina. En: Mackintosh M, Koivusolo M, organizadores. Commercialization of health care: global and local dynamics, and policy responses. Hampshire: Palgrave Macmillan (Macmillan Publishers Limited); 2005.
5. Foster JB. The financialization of capitalism. Monthly Review 2007; 58(11):1-12.
6. Bello W. Dilemmas of domination. The unmaking of the American empire. New York: Metropolitan Book Henry Holt and Co; 2005.
7. Petras J. La globalización: un análisis crítico. En: Saxe-Fernández J. Petras J, Veltemeyer H. Núñez O, editores. Globalización, imperialismo y clase social. Buenos Aires: Lumen; 2001.
8. Iriart C, Merhy E, Waitzkin H. Managed care in Latin America: the new common sense in health policy reform. Soc Sci & Med 2001; 52:1243-1253.
9. Waitzkin H. The strange career of managed competition: from military failure to medical success? Am J Public Health 1994; 84(3):482-489.
10. Stocker K, Waitzkin H, Iriart C. The exportation of managed care to Latin America. N Eng J Med 1999; 340(14):1131-1136.
11. Kuttner R. Must good HMOs go bad? First part. N Eng J Med 1998; 338(21): 1558-1563.
12. Kuttner R. Must good HMOs go bad? Second part. N Eng J Med 1998; 338(22):1635-1639.
13. Starr P. The social transformation of American medicine. New York: Basic Books; 1982.
14. Iriart C. Atención gerenciada en América Latina: su papel en la reforma de los sistemas de salud. Salud, Problema y Debate 1999; 21:5-18.
15. Himmelstein D, Woolhandler S, Hellander I, Wolfe S. l. Quality of care in investor-owned vs not-forprofit HMOs. JAMA 1999; 282(2):159-163.
16. Iriart C, Waitzkin H, Merhy E. HMO's abroad: managed care in Latin America. En: Fort M, Mercer M, Gish O, editors. Sickness and wealth. The corporate assault on global health. Cambridge, MA: South End Press; 2004
17. Iriart C. Atenção gerenciada: instituinte da reforma neoliberal [tese]. Campinas (SP): Faculdade de Ciências Médicas; 1999.
18. Iriart C, Waitzkin H. Argentina: no lesson learned. Int J Health Serv 2006; 36(1):177-196.
19. Agência Nacional de Saúde Suplementar. Duas faces da mesma moeda: microrregulações e modelos assistenciais na saúde suplementar. Rio de Janeiro: ANS; 2005.
20. Kassirer J. On the take. How medicine's complicity with big business can endanger your health. New York: Oxford Press; 2005.
21. Guerra J. La política de medicamentos en la década del '90 en Argentina. Salud, Problema y Debate 1997; 7(15):23-31.
22. Guerra J. Las corporaciones farmacéuticas y su mercado global. Salud, Problema y Debate 2000; 9(22):1-16.
23. Moynihan R, Henry D. The fight against disease mongering: Generating knowledge for action. Plos Med 2006; 3(4):425-8.
24. Geyman J. Health care in America. Can our ailing system be healed? Boston: Butterworth Heinemann; 2002.
25. Evidence-based medicine working group. Evidence-based medicine: a new approach to teaching the practice of medicine. JAMA 1992; 268:2420-5.
26. Tonelli MR. The philosophical limits of evidence-based medicine. Acad Med 1998; 73(12):1234-40.
27. Lexchin J. Bigger and better: How Pfizer redefined erectile dysfunction. Plos Med 2006; 3(4):429-32.
28. Tiefer L. Female sexual dysfunction: a case study of disease mongering and activist resistance. Plos Med 2006; 3(4):436-40.
29. Healy D. The latest mania: Selling bipolar disorder. Plos Med 2006; 3(4):441-4.
30. Phillips C. Medicine goes to school: teachers as sickness brokers for ADHD. Plos Med 2006; 3(4):433-5.
31. Moynihan R, Cassels A. Selling sickness: how the world's biggest pharmaceutical companies are turning us all into patients. New York: Nation Books; 2005.
32. Angell M. The truth about the drug companies: how they deceive us and what to do about it. New York: Random House; 2004.
33. Critser G. Generation Rx. How prescription drugs are altering American lives, minds, and bodies. New York: Houghton Mifflin; 2005.
34. Applbaum K. Pharmaceutical marketing and the invention of the medical consumer. Plos Med 2006; 3(4):445-7
35. Lakoff A. The anxieties of globalization. Antidepressant sales and economic crisis in Argentina. Social Studies of Science 2004; 34(2):247-269.
36. Mintzes B. Disease mongering in drug promotion: Do governments have a regulatory role? Plos Med 2006; 3(4):461-5.
37. Fitzpatrick M. The tyranny of health. Doctors and the regulation of lifestyle. London & New York: Routledge; 2001.